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Abstract
The Miro GTPases represent an unusual subgroup of the Ras superfamily and have recently emerged as important mediators of
mitochondrial dynamics and for maintaining neuronal health. It is now well-established that these enzymes act as essential
components of a Ca2+-sensitive motor complex, facilitating the transport of mitochondria along microtubules in several cell
types, including dopaminergic neurons. The Miros appear to be critical for both anterograde and retrograde mitochondrial
transport in axons and dendrites, both of which are considered essential for neuronal health. Furthermore, the Miros may be
significantly involved in the development of several serious pathological processes, including the development of neurodegen-
erative and psychiatric disorders. In this review, we discuss the molecular structure and known mitochondrial functions of the
Miro GTPases in humans and other organisms, in the context of neurodegenerative disease. Finally, we consider the potential
human Miros hold as novel therapeutic targets for the treatment of such disease.
Keywords Miro GTPase . Neurodegenerative disease . Parkinson’s disease . Mitochondria . Atypical GTPase . Amyotrophic
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The Miro GTPases: Regulators
of Mitochondrial Function
Mitochondria are essential for energy production, neuronal func-
tion, cellular survival and control of intracellular calcium homeo-
stasis [1, 2]. Mitochondrial ATP production supports essential
neurological functions including generation of membrane poten-
tial, spike potential, mobilisation of synaptic vesicles and medi-
ating presynaptic development [3, 4]. In addition, mitochondria
play a critical role in mediating calcium homeostasis during neu-
ronal stimulation and regulate neurotransmission and short-term
plasticity [5–8]. In order to maintain this plethora of functions
including mitochondrial movement, morphology, fission, fusion
and ATP production, the individual processes need to be very
finely regulated. Two different mitochondrial Rho GTPases,
Miro1 and Miro2, have been shown to play an intricate role in
all of these mitochondrial functions. Since abnormalities in mi-
tochondrial function strongly associate with various neurological
dysfunctions, understanding the role of Miro1 and Miro2 re-
mains vital to understanding several human neuropathologies.
Initially classified as typical Rho GTPases [9], the Miro
GTPases (‘mitochondrial Rho GTPases’) are now considered
a subclass of the Ras monomeric GTPase superfamily
[10–12]. The Miro subfamily contains only the two genes
encoding the Miro GTPases present in humans, namely
Miro1 and Miro2 (alternatively referred to as RhoT1 and
RhoT2) [9]. Anchored to the mitochondrial outer membrane
(MOM) by means of a C-terminal transmembrane sequence
[12, 13], the Miro proteins are accessible to the cytoplasm,
where they are involved in a variety of mitochondria-related
processes, including the morphology and homeostasis, anter-
ograde and retrograde movement of mitochondria [14–18].
Considering the importance of healthy mitochondria in neu-
ronal function, in addition to the strong implication of dys-
functional mitochondria in psychiatric disorders such as
schizophrenia and neurodegenerative conditions such as
Alzheimer’s disease (AD) and Parkinson’s disease (PD) [7,
19–22], a comprehensive understanding of the Miro proteins
holds significant clinical importance.
Laura Kay and Ilse S. Pienaar contributed equally to this work.
* Meera Soundararajan
meera.soundararajan@northumbria.ac.uk
1 Department of Applied Sciences, Faculty of Health and Life
Sciences, Northumbria University, Newcastle NE1 8ST, UK
2 School of Life Sciences, University of Sussex, Falmer BN1 9PH, UK
Molecular Neurobiology (2018) 55:7352–7365
https://doi.org/10.1007/s12035-018-0927-x
Molecular Structure of the Miro GTPases
The Miro GTPases are the only human proteins comprising
two different GTPase domains in the same polypeptide chain.
A pair of Ca2+ binding helix-loop-helix topology containing
EF-hand domains is flanked by the two GTPase domains [9,
11, 13, 14, 23–29] (Fig. 1). Both human Miros consist of 618
amino acid residues, sharing 60% amino acid identity between
them [9, 13, 27]. The Miro GTPases contain a transmembrane
domain required for targeting to the MOM where they are
anchored at the C-terminus, with the majority of the protein
accessible to the cytoplasm [12, 13, 30, 31] (Fig. 1). Of these
GTPase domains, the N-terminal GTPase domain is the most
well-studied and, structurally, most similar to Rho GTPases
[27]. Conversely, the C-terminal GTPase domain appears sim-
ilar to Rheb, a protein of the Ras sub-family by sequence
homology [12, 13].
Despite the N-terminal GTPase domain’s similarity to
Rho GTPases, initial classification of the Miro GTPases
as members of the Rho sub-family was disregarded when
both GTPase domains were found to lack the conserved G-
3 DxxG motif [17, 32–34] and Rho-specific insert helix
[18, 27, 35, 36], a surface-exposed alpha-helical domain
unique to the Rho GTPases. The two EF-hand domains of
Miro have been shown to bind Ca2+ [16, 23] and the bor-
dering regions of these domains appear highly conserved
amongst eukaryotes [23, 24]. A recent crystallographic
study showed that these bordering regions contain non-
canonical ‘hidden’ EF-hands (hEF-hands) proceeded by
single helices (LM helices 1 and 2) in the single drosophila
Miro (dMiro) orthologue [23]. In dMiro, these hEF-hands
exhibit a helix-loop-helix structure capable of stabilising
local EF-hands via formation of an anti-parallel EF-hand
β-scaffold. The structure of the LM helices, however, is
similar to that of extrinsic ligands bound to EF-hand pro-
teins, as described for the protein complexes of moluscan
myosin heavy and light chain [23, 29], as well as troponin I
and troponin C [37]. These structural features are shown to
be highly conserved in human Miro x-ray crystallographic
structures reported recently [38]. This combination of EF-
hEF hands followed by an LM helix has been observed in a
variety of other Ca2+ binding proteins, including recoverin,
the neuronal calcium binding protein found in photorecep-
tor [24, 35, 39, 40], the pollen protein polcalcin which is
implicated as a panallergen [41] and a human guanylate
cyclase-activating protein (GCAP3), a calcium-dependent
guanylate cyclase receptor in phototransduction pathways
[25, 36, 41]. The domain architecture and subatomic struc-
tures of the Miros suggests that these proteins have struc-
turally and functionally evolved to cater as GTPases, with
an N-terminal domain and unique ‘putative catalytic do-
main’ in the C-terminus, in addition to modified EF-
hands that can function as calcium sensors.
Miro Facilitates Mitochondrial Transport
Awell-documented function of Miros is the central role they
play in the transport of mitochondria [9, 11, 13–18, 42, 43],
facilitated by the action of kinesins and dyneins acting as
anterograde and retrograde motors, respectively [44]. In some
motor neurodegenerative disorders, deficiencies in mitochon-
drial transport are most notable in neuronal cells, where effi-
cient transport of mitochondria from the nucleus to compo-
nents with high energy demands, such as synaptic terminals, is
critical for healthy neuronal function and survival [45].
However, retrograde mitochondrial movement also appears
crucial in neuronal health [46].
A search for genes necessary for axonal and synaptic func-
tion in Drosophila melanogaster revealed key roles for dMiro
in the transport of mitochondria from the neuronal soma to
distal synapses [14]. Glater and colleagues reported that a
protein complex composed of dMiro and the kinesin-
associated protein Milton enable the anterograde transport of
mitochondria via apparent recruitment of kinesins [47]. Two
mammalian homologues of Milton, trafficking kinesin-
binding protein 1 (TRAK1) (also known as OIP106) and traf-
ficking kinesin-binding protein 2 (TRAK2) (also known as
OIP98/Grif-1), capable of forming complexes with mamma-
lian Miro1 and Miro2 and with microtubule motors, have also
been shown to co-localise with human Miros (hMiros) [15],
indicating that these proteins act as a component of a con-
served protein complex necessary for mitochondrial transport
(Fig. 2).
The anterograde motor kinesin-1 (also referred to as
kinesin heavy chain (Kif5)) and the retrograde motor (the
dynein/dynactin complex) were shown to facilitate the trans-
port of many cellular cargoes along microtubules [48]. These
motor proteins are bound to mitochondria by interacting with
two mitochondria-specific proteins: Miro and Milton (or the
Fig. 1 Domain architecture of human Miro GTPase. The amino terminal
and carboxy terminal GTPase domains are shown in light and dark blue,
respectively. The two calcium binding EF-hand domains, flanked by the
catalytic domains, are depicted in light and dark green. The extreme C-
terminal transmembrane domain responsible for anchoring mitochondria
to the outer membrane is shown as a pink rectangle
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Milton homologues TRAK1 and TRAK2 in mammals). Miro
anchors to the mitochondrial outer membrane while Milton
serves as an adaptor protein, linking the motor proteins to
Miro and therefore to mitochondria. The resulting protein
complex is believed to facilitate the movement of mitochon-
dria along microtubules [13, 15–17].
Interestingly, while the concept of the Miro/Milton
(TRAK) transport complex is widely accepted, direct (Ca2+-
dependent) binding of hMiro1 to kinesin motor Kif5 has been
demonstrated, indicating a degree of redundancy for a Milton-
like adaptor protein [16]. In contrast, TRAK2 and hMiro1
have been shown to directly form a protein complex and co-
localise with mitochondria in mammalian brain tissue extracts
[15]. Furthermore, the GTPase state of the hMiro1 N-terminal
GTPase domain appears to recruit TRAK2 to mitochondria in
mammalian cell lines, producing downstream effects on an-
terograde mitochondrial movement [15]. Indeed, over-
expression of hMiro1 appears to increase TRAK2 recruitment
to mitochondria that, in turn, encourages anterograde mito-
chondrial transport. Correspondingly, abolishing the kinesin-
binding domain in TRAK2 impairs anterograde movement of
mitochondria [15]. This suggests that transport of mitochon-
dria in mammals is mediated by a mechanism dependent on
the N-terminal GTPase domain for recruitment of TRAK to
the mitochondria and that the resulting Miro-TRAK-kinesin
protein complex is required for anterograde movement of mi-
tochondria along microtubules. However, retrograde mito-
chondrial movement may also be affected by aberrant Miro
function, with recent live-imaging of GFP-tagged mitochon-
dria showing that dysfunctional dMiro results in the impair-
ment of both anterograde and retrograde mitochondrial trans-
port [17]. Indeed, both Miro1 and Miro2 coupled with the
disrupted in schizophrenia 1 (DISC1) protein, influencing
the mitochondrial transport and fusion machinery via the
TRAK1 and TRAK2 molecular adapters [49]. Analysing the
role of DISC1 and proteins associated with mitochondrial dy-
namics has recently revealed that disruption of the DISC1
Miro/TRAK complex inhibits mitochondrial transport in neu-
rons [49, 50]. Characterisation revealed that the Miro-DISC
complex acts as a regulatory unit in mediating mitochondrial
dynamics in both axons and dendrites [49, 50]. This is of note
since it provides compelling evidence that the Miro-TRAK
complex can play a role not just in axons, as previously
shown, but also in dendritic mitochondrial trafficking [50, 51].
Despite the suggestion that a Milton/TRAK adaptor could
be redundant under some disease conditions due to direct
Miro-kinesin motor binding [16], both TRAK1 and TRAK2
have been directly linked to mitochondrial motility [13,
15–17]. Indeed, recent studies suggest a link between nutri-
ents available to neurons and mitochondrial motility through
glucose signalling and subsequent modification of TRAK1
and 2 [52, 53]. In this regard, extracellular glucose was shown
to activate O-GlcNAc transferase (OGT), an enzyme that ca-
talyses post-translational O-glycosylation of target proteins
[52]. Proteomic investigations suggest that activated OGT tar-
gets TRAKs for GlcNAcylation, leading to the arrest of mito-
chondrial motility [53].
Taken together, accumulating evidence suggests that a
Miro/Milton (TRAK)/motor transport complex is involved
in the transportation and motility of mitochondria and that this
is sensitive to signalling from within the complex [15, 16],
from intracellular components [23, 50] and from external fac-
tors such as extracellular glucose levels [52, 53]. Interestingly
a very recent study from Melkov and others [54] presents an
alternative model for mitochondrial transport by Miro-based
motor complex where they differentiated the mitochondrial
anterograde and retrograde movement using Drosophila bris-
tle cells that mimic neurons. Here, they show through a
Fig. 2 Miros in mitochondrial movement. The Miros act within an
integrated machinery with TRAK1/2 to facilitate the anterograde and
retrograde movement of mitochondria along microtubules. Both axonal
and dendritic mitochondrial transport aremediated by theMiros, although
they appear to engage different transport machineries to achieve this.
TRAK1 binds to both kinesin-1 and dynein/dynactin and is
predominantly localised in axons, while TRAK2 preferentially binds
dynein/dynactin and exhibits dendritic localization. The interaction of
TRAK1 with both the kinesin (anterograde) and dynein (retrograde)
motors enable movement in both directions in the axon, while
TRAK2’s more favourable interactions with dynein may encourage
retrograde movement at neurons’ distal ends. Only the anterograde
movement is shown in this figure. Miro EF-hands are represented by
yellow rectangles; calcium is represented by red spheres. The molecules
and mitochondria are not depicted to scale
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microtubule gliding assay the dynein-mediated bidirectional
mitochondrial transport was mediated by Miro in retrograde
mitochondrial transport while Milton was observed to be re-
sponsible for primary polarised mitochondrial sorting into the
developing bristle cells [54]. The study shows lymphocyte
mitochondria specifically redistribute to the adhesion zone in
close contact with the endothelium. Miro-1, through the reg-
ulation of mitochondrial movement along microtubules and
its association with dynein/dynactin motors, influences mito-
chondrial positioning. Deficiency in Miro-1 prevents correct
interaction with inflamed endothelium, lymphocyte
polarisation and chemotactic migration.
The Miro GTPases Facilitate Ca2+-dependent
Transport of Mitochondria
While the necessity of the Miro/TRAK/motor complex in mi-
tochondrial transport is widely accepted, the role of cytosolic
Ca2+ in relation to this complex remains disputed. Cytosolic
Ca2+ is required for mitochondrial transport, which is arrested
in the presence of increased intracellular Ca2+ [55].
Interestingly, the Miro EF-hands are not only involved in
binding calcium [56], but in sensing the influx of Ca2+ during
synaptic activation, triggering conformational changes in
Miro to regulate the protein-protein complexes and binding
of effector molecules through the N-terminal GTPase domain
effector loop [57]. This is crucial since Ca2+ sensing and the
regulation of intermolecular interaction dictates mitochondrial
immobilisation at active synapses [16, 18, 57]. Various pre-
dictive models have been proposed regarding the link between
Miro, Ca2+, and mitochondrial transport (Fig. 2). One model
stipulates that increased cytosolic Ca2+ initiates dissociation of
the kinesin motor from microtubules and that the subsequent
interaction of kinesin with Miro on the mitochondrion results
in the dissociation of motors from the microtubules (Fig. 2).
An alternative model suggests that Miro binds directly to
kinesin without the need for the Milton adaptor, and that in-
creased cytosolic Ca2+ inhibits Miro’s interaction with
kinesin, leading to direct uncoupling of Miro from kinesin
[16] (Fig. 2). However, the arrest of mitochondrial transport
in neurons has also been linked to the mitochondrial tethering
protein syntaphilin (SNPH), resulting in a third model being
proposed. In this so-called Engine-Switch and Brake model,
increased cytoplasmic Ca2+ dissociates kinesin fromMiro [58,
59] (Fig. 2). Following dissociation, kinesin then interacts
with SNPH, disrupting the ATPase activity of kinesin and
resulting in the arrest of mitochondrial motility. Thus, SNPH
performs as an ‘engine-off’ switch by detecting Ca2+-induced
arrest of mitochondria, and also as a brake, by securing static
mitochondria to the microtubules.
An alternative proposition holds that intra-mitochondrial
Ca2+, rather than cytosolic Ca2+, plays a critical role in
mediating mitochondrial transport, and that Miro is involved
in orchestrating intra-mitochondrial Ca2+ levels [59].
Mitochondria buffer cytoplasmic Ca2+ via uptake of Ca2+
through the mitochondrial calcium uniporter (MCU) [60].
The uptake of Ca2+ through the MCU was shown to be in-
versely related to mitochondrial velocity in axons, thus illu-
minating a mechanism by which cytosolic Ca2+ influences
mitochondrial trafficking [59]. Two independent studies have
demonstrated that expression of Miro1 at the mitochondrial
outer membrane affects the concentration of Ca2+ in the mito-
chondrial matrix [18, 59]. As elevated intra-mitochondrial
Ca2+ has been associated with slower movement or stopping
the movement of mitochondria, alongside a subsequent in-
crease in ATP production, these results indicate that a link
exists between mitochondrial motor machinery, mitochondrial
trafficking and the mediation of bioenergetic efficiency in mi-
tochondria [61, 62].
The Miro GTPases in Mitochondrial
Morphology
The influence ofMiro onmitochondrial morphology appears to
be strongly conserved. Initial functional studies in mammalian
cells showed perinuclear aggregation of mitochondria when a
mutant of hMiro1 bearing a constitutively active N-terminal
GTPase domain was over-expressed [9]. A similar effect was
obtained from over-expression of a mutant of hMiro1
harbouring a dominant-negative N-terminal GTPase domain,
though to a lesser extent [9]. These results imply that a balanced
level of Miro activity in the N-terminal GTPase domain of
hMiros is necessary for the maintenance of normal mitochon-
drial morphology. The single Miro protein of Saccharomyces
cerevisiae, Gem1p, appears to require both GTPase domains
and functional EF-hands for the maintenance of normal mito-
chondrial morphology [11]. A 662-amino acid protein, Gem1p
shares 30% amino acid identity with the human Miros. When
Gem1pwas ablated in S. cerevisiae (Gem1pΔ cells), mitochon-
dria exhibited both abnormal distribution and abnormal mor-
phology, with a collapsed, globular or ‘grape-like’ appearance
[28]; however, such mitochondria retained inner cristae struc-
tures when viewed under transmission electron microscopy.
A role for Miro in mitochondrial morphology has also been
observed inDrosophila, with overexpression of wild-type dMiro
producing significant aggregation of mitochondria in dopaminer-
gic neurons [43] and abnormally elongated mitochondria in lar-
val motor neurons [17, 43]. However, the effects of dMiro on
mitochondrial morphology may be dependent on context and
cell type in vivo; if so, this would suggest that dMiro is not
directly involved in modulating mitochondrial morphology but
perhaps that one or more binding partners are necessary to exert
the effects onmitochondrial morphology observed previously [9,
17, 63].
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Early research on the human Miros [9, 27] concentrated on
the creation of Miro mutants containing amino acid substitutions
in the N-terminal GTPase domain, making this GTPase domain
either constitutively active (G13V) or dominant negative (S18N)
with respect to GTP/GDP-bound status. Ectopic expression of
Miro1 mutants bearing the constitutively active N-terminal
GTPase domain (Miro1 V13) induced a collapse of the mito-
chondrial network in non-neuronal cells, with mitochondria
exhibiting perinuclear aggregation [9]. Ectopic expression of this
mutant was associated with increased presence of the apoptotic
marker M30 (recognising caspase-cleaved cytoskeleton-18) rel-
ative to both cells expressing wild-type Miro1 and cells ectopi-
cally expressing S18N Miro1 mutants. Correspondingly, the in-
troduction of caspase inhibitors reduced this increase in M30,
suggesting a role for the GTP/GDP-bound status of the Miro1
N-terminal GTPase domain in apoptosis. However, while over-
expression of Miro in other organisms has produced a similar
pattern of mitochondrial aggregation, other studies have failed to
demonstrate a clear link between Miro overexpression and apo-
ptosis [9, 27].
The Miro GTPases in Mitochondrial Fission
and Fusion
Mitochondrial fission, fusion, and transport play important roles
in healthymitochondrial network [1, 2, 64]. The balance between
fusion and fission controls mitochondrial morphology, which is
mediated by a number of enzymes including the Miro GTPases
(see Fig. 3). A recent effort to identify regulators of Miro identi-
fied that Vimar in Drosophila, and its mammalian homologues
RAP1GDS1, regulated mitochondrial morphology. The Vimar
homologues function as guanine nucleotide exchange factor
(GEF) proteins, regulating mitochondrial fission in response to
calcium concentrations. Under normal cellular conditions, Miro
increases mitochondrial size by inhibiting Drp1 [43, 63]; howev-
er, at high concentrations of Ca2+, Miro interacts directly with
Vimar homologues and promotesmitochondrial fission [65]. The
mitochondrial enlargement observed in the Drosophila model
PD was rescued through loss of Vimar expression [65].
RAP1GDS, the mammalian homologue of Vimar, exhibits the
conserved biological function seen in Drosophila. Targeting the
human Miro/RAP1GDS1 complex through peptides or small
molecule drugs may therefore prove a promising therapeutic
approach, avoiding any off-target effects that could occur by
singling out individual molecules as targets.
Effects on ATP Homeostasis
While Miro 1 appears abundantly expressed in heart and skel-
etal muscle, Miro 2 expression is most prominent in heart,
liver, kidney, pancreas and skeletal muscle tissue [9]. This is
particularly interesting with regards to the high energy de-
mand these cell types commandeer, suggesting perhaps that
theMiro GTPases are involved in ATP homeostasis or cellular
bioenergy homeostasis. Indeed, a Gem1p abrogation strain in
S. cerevisiae grew significantly slower on glycerol minimal
media relative to wild type cells, suggesting that yeast Miro
homologue Gem1p is necessary for correct mitochondrial res-
piration [11]. Too, the single Miro homologue GemA in
Dictyostelium discoideum appears to play a role in mitochon-
drial respiration, with GemA knockout mutants exhibiting im-
paired cell growth on nutrient media alongside reduced ATP
content and increased oxygen consumption [24]. This func-
tion of Miros in maintaining ATP homeostasis is likely to be
conserved across species.
Animal Models of Miro Abrogation
The function of the Miro enzymes has been evaluated in sev-
eral different model organisms. Most closely related to Miro1
in humans, dMiro represents a single Miro protein expressed
in Drosophila. Mitochondria in mutant dMiro neurons was
adversely altered relative to wild-type controls, with neat clus-
tering of mitochondria observed towards the soma of mutant
larval neurons and an absence of mitochondria noted at distal
neuronal structures, such as neuromuscular junctions [14].
Drosophila mutant larvae presented with a slim body relative
to wild type, with abnormally small muscle size and progres-
sive locomotive defects including increasing levels of paraly-
sis, culminating in death at either the larval or early pupal
stage. This phenotype was rescued by expressing wild-type
dMiro in neurons, but not in muscle cells, suggesting a critical
role for dMiro in neuronal function and survival [14].
Interestingly, mutations affecting axonal transport often pres-
ent with abnormal pre-synaptic vesicle accumulation, and typ-
ically, this state of accumulation is a marker of neuropatholo-
gy [66–68]. While vesicular transport appeared impaired in
dMiro mutant neurons, however, this effect was qualitatively
and quantitatively diverse from the significant defects in mi-
tochondrial transport observed [14]. Thus, while the impair-
ment of vesicular transport may have contributed to the ob-
served dMiro mutant phenotype, it is unlikely that both trans-
port defects were the consequence of a shared mechanism.
Other than the dMiro mutant flies, recent global and
neuron-specific Miro1 mouse knockouts have been developed
[69]. Mice globally deficient of Miro1 were cyanotic and died
shortly following birth. The Miro1 neuron-specific knockout
mouse phenotype was also striking, exhibiting rapidly
progressing upper motor neuron disease symptoms and early
death after approximately 4 weeks. At birth, the neuron-
specific Miro1−/− mice appeared indistinguishable from WT
littermates. However, by 2 weeks, Miro1−/− mice exhibited
hind-limb clasping, a known early marker for neuronal
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impairment. These mice failed to gain weight as they matured
and developed a stiff tail, spinal curvature (kyphosis), hind-
limb spasticity, and progressive locomotive defects. This phe-
notype was reflective of the development of upper human
amyotrophic lateral sclerosis (ALS), with symptoms becom-
ing progressively worse and premature death occurring at ap-
proximately 35 days. Impaired retrograde transport of mito-
chondria was implicated in the development of this pheno-
type, rather than the anterograde transport impairment strong-
ly implicated in earlier studies. However, the previously ob-
served perinuclear aggregation of mitochondria was shown in
mouse embryonic fibroblasts obtained from Miro1−/− mice
[69]. No significant differences were reported in mitochondri-
al respiration or mitochondrial membrane potential in Miro1−/
− cells relative to controls, indicating that defective mitochon-
drial transport was the primary cause of the mutant pheno-
types, but that this transport was not influenced by defective
mitochondrial respiration or membrane potential.
The Miro GTPases in Neuronal Pathology
The Miro GTPases appear to play a critical role in the main-
tenance of neuronal health. This is perhaps unsurprising when
one considers the crucial role the Miros appear to play in
mitochondrial transport (discussed previously) coupled with
the need for mitochondria to travel vast distances in neurons
along axons (which can be up to ~ 1 m long) from the soma
towards the distal synaptic end for neural transmission
[70–72]. Indeed, altered Miro function has been associated
with CNS pathologies such as PD [43, 73], and ALS [14,
69, 74]. Moreover, disruption of mitochondrial dynamics by
targeting the DISC1-Miro/TRAK complex or upon expres-
sion of the DISC1-Boymaw fusion protein impairs the correct
development of neuronal dendrites [51].
The Role of the Miros in Development
of Upper Motor Neuron Disorders
An investigation into the role of the Miros in upper motor
neuron development and mitochondrial retrograde transport
using mouse knockouts (KO) clearly demonstrated a compel-
ling role for Miro1 in neurological disorders through its influ-
ence of mitochondrial motility [69]. In this study, Nguyen and
colleagues showed that the Miro1 mouse KO clearly
displayed physical hallmarks of neurological disease in the
brainstem and spinal cord [69]. The mice developed rapidly
Fig. 3 Miro in Parkinson’s disease. A = LRRK2, promotes Miro removal
by forming a complex with Miro. Pathogenic mutant LRRK2G2019S
disrupts this function, delaying the arrest of damaged mitochondria and
consequently slowing the initiation of mitophagy. Mitochondrial motility
and Miro degradation are shown to be impaired in PD patients. Direct
interaction of LRRK2 with Miro results in Miro removal from
mitochondria. In pathogenic LRRK2 mutant G2019S this is deranged
delaying the arrest of damaged mitochondria and consequently slowing
the initiation of mitophagy. Knockdown in Miro levels in LRRK2G2019S
human neuron and Drosophila PD models rescued neurodegeneration.
Miro degradation and mitochondrial motility are also impaired in
sporadic PD patients. B = Parkinson’s disease implicated PINK1 kinase
and Parkin play an important role in quality control of mitochondrial
survival and apoptosis through Miro GTPase. Dysfunctional
mitochondria are destroyed after PINK1 accumulation that
phosphorylated Miro at S156 and also Parkin to activate its E3 ligase
activity. This results in proteosomal degradation of Miro and
mitochondrial arrest and mitophagy
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progressing uppermotor neuron disease symptoms in 4weeks.
The role of Miro in mitochondrial motility is therefore worthy
of consideration, as the defects in mitochondrial motility
caused by Miro1 was shown to be sufficient to cause progres-
siveMND. Hence, a complete understanding of the causal and
possible therapeutic role of Miros in upper MNDs such as
spinal cord injury, cerebral palsy, multiple sclerosis and ac-
quired brain injury including stroke remains to be established.
Miro Proteins in Parkinson’s Disease
It is estimated about 10 million people live with PD world-
wide and approximately 60,000 Americans are diagnosed
with PD every year [75]. Although PD is typically diagnosed
in individuals above age 65 [76], diagnosis in patients below
age 65 is increasing [77]. In 2010, the total cost of PD was
€13.9 billion in Europe [78] and $14.4 billion in the USA [79],
with costs projected to progressively increase [79, 80]. PD is
characterised by the degeneration of dopaminergic neurons
and/or loss of neuronal projections in several dopaminergic
networks [81]. Current treatments for idiopathic PD relymain-
ly on the use of pharmacologic agents to improve disease
symptoms [82]. Since PD remains an incurable disease, it is
crucial to establish new therapeutic strategies for PD treat-
ment. It is therefore of great clinical interest to identify PD
biomarkers and validate novel drug targets with the ageing
population increasing worldwide every year.
Interestingly, PD has been consistently associated with mi-
tochondrial dysfunction [83, 84]. Indeed, several reliable PD
animal models rely on exposure to mitochondria toxins, such
as MPTP [85] and rotenone [86]. Furthermore, some mono-
genetic forms of PD are mitochondria-related. For example,
mutations in leucine-rich repeat kinase 2 (LRRK2) are asso-
ciated with autosomal dominant PD [87] and have been im-
plicated in mitochondrial fragmentation and increased apopto-
tic rates relative to wild-type LRRK2 [88–90].
(see Fig. 3). Moreover, LRRK2 has been shown to partially
co-localise with mitochondrial fission dynamin-like protein 1
(DLP1) in cortical neurons, suggesting that pathogenic LRRK2
mutants may be associated with PD through disturbances in mi-
tochondrial fission [90]. As discussed below, mutations in the
PTEN-induced putative kinase 1 (PINK1) and E3 ubiquitin li-
gase Parkin have also been linked to mitochondrial-related auto-
somal recessive manifestations of PD [91].
InDrosophila, overexpression of dMiro has been demonstrat-
ed as toxic, producing an age-dependent loss of dopaminergic
(DA) neurons, the neurons specifically affected in the substantia
nigra of PD patients [92, 93]. The exact process by which this
dMiro overexpression produces toxicity remains obscure.
However, Miro GTPases are known to be associated with pro-
teins involved with PD when dysfunctional: the mitochondria-
localised PINK1 and Parkin, an E3 ubiquitin ligase usually
localised in the cytoplasm [94]. Under normal circumstances,
PINK1 and Parkin proteins form crucial components of a mito-
chondrial quality control system aimed at targeting damaged
mitochondria for isolation and mitophagy, in order to sustain
cellular metabolic requirements and prevent damage caused by
defective mitochondria [95, 96]. Loss-of-function mutations in
PINK1 and Parkin are associatedwith rare recessive forms of PD
[97]. Mitochondrial damage results in PINK1 accumulation on
the outer mitochondrial membrane (OMM) and recruitment of
Parkin from the cytosol to mitochondria. Upon recruitment,
Parkin ubiquitinates various substrates on the OMM [VDAC1,
dynamin-related protein 1 (Drp1), Mfns, translocase of outer
mitochondrial membrane 20 (TOM20) and TOM40], allowing
for initiation of mitophagy by the ubiquitin/proteasome pathway
[98, 99]. Interestingly, Miro appears to interact with PINK1 and
Parkin and is ultimately targeted for ubiquitination by Parkin
when mitochondrial damage occurs. In a Drosophila PD model
involving loss of PINK1 function, reduced dMiro function im-
proved the degenerative phenotype shown in PINK1mutant DA
neurons. This suggests a role for mitochondrial transport and
Miro in PINK1-related PD pathogenesis [92], a notion further
supported by the profound effects seen in altered PINK1 function
on the transportation of axonalmitochondria inDrosophila larval
motor neurons or mammalian hippocampal neurons. Indeed,
Miro appears to be specifically targeted for degradation by
PINK1 and Parkin in vivo inDrosophila or in cultured mamma-
lian cells treated with the mitochondrial toxin carbonyl cyanide
m-chlorophenylhydrazone (CCCP) [92, 100, 101]. Whether
Miro is a direct substrate of PINK1-mediated phosphorylation
or whether this phosphorylation is a prerequisite for the regula-
tion of Miro stability by PINK1 and Parkin remains unknown
[92, 102]. Miro has previously been shown to undergo PINK1-
mediated phosphorylation at Ser156 and that phosphorylation at
this site is necessary for degradation of Miro by Parkin [73]. The
loss of hMiro in HeLa cells resulted in the perinuclear aggrega-
tion of mitochondria and facilitated in increased mitophagy, a
phenotype previously associated with activation of the PINK1/
parkin pathway [92]. It has also been postulated that Miro may
form a constituent of the Parkin receptor complex, as hMiro1
appears capable of stabilising phospho-mutant versions of
Parkin on the OMM. The regulation of Miro stability and turn-
over by PINK1 and Parkin could perhaps act to isolate damaged
mitochondria from the network, promoting their transport to the
cell body and subsequent degradation. However, further studies
are required to elucidate the underlying molecular interplay be-
tween Miro, PINK1 and Parkin using PD patient samples.
Miro Proteins in ALS
ALS, also known as motor neuron disease, is characterised by
progressive upper and lower motor neuron degeneration,
resulting in severe limb and trunk muscle weakness, and
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eventual paralysis [103]. Several studies have described al-
tered expression levels and/or dysfunctional Miro in ALS pa-
tients or animal models of the disease. This included a report
of significantly reduced levels of Miro1 present in spinal cord
samples of ALS patients [104]. In addition, the same group
found that protein levels were also depleted in an experimental
model of the disease, using transgenic mice expressing famil-
ial ALS-associated mutations in genes encoding copper-zinc
superoxide disputes 1 (SOD1) G93A or TAR DNA-binding
protein 43 (TDP-43) M337V, with these mutant mice
displaying a phenotype that closely resembles clinical ALS.
In the transgenic mice, the Miro1 protein levels were found to
be reduced exclusively in the spinal cord, and not in brain
tissue, potentially explaining the selective vulnerability of mo-
tor neurons in the spinal cord during ALS. The authors con-
cluded that the Miro1 deficiency observed in this study may
explain the impaired intracellular distribution of mitochondria
seen in ALS [105].
Mutations in SOD1 have previously been shown to impair
axonal transport of mitochondria in motor neurons isolated
from SOD1 G93A transgenic mice, similar to what is seen
in ALS-associated mutant SOD1 transfected cortical neurons
[106]. A recent investigation by Moller and colleagues [107]
revealed the mechanism underlying dysfunctional axonal
transport of mitochondria in mutant SOD1-related ALS. The
study found that the expression of ALS-related mutant SOD1
reduced the level of endogenous Miro1, and that such reduc-
tions were dependent on an E3 ubiquitin-ligase Parkin, which
acts downstream of the Ser/Thr-kinase, PINK1. The PINK1/
Parkin pathway quarantines damaged mitochondria prior to
their clearance through the phosphorylation of Miro by
PINK1, which instigates Parkin-dependent ubiquination, and
thus the degradation of Miro1, to consequently halt mitochon-
drial transport in axons [73]. However, another study failed to
observe PINK1-dependent Miro phosphorylation, and also
could not validate the requirement of Miro’s phosphorylation
for subsequent degradation [43]. Yet, the study by Moller and
others [107] provided evidence for a PINK1-Parkin-
dependent mechanism underlying Miro1 degradation, with
the additional finding that expression of ALS mutant SOD1
inhibits axonal transport of mitochondria by activating this
pathway.
Calcium binding to Miro1 has been shown to halt antero-
grade mitochondrial axonal transport by modifying Miro1’s
interaction with the motor domain of kinesin-1 via an adaptor
protein,Milton. On the other hand, it’s been shown that the EF
handmotif of Miro can mediate Ca2+-dependent arrest of both
retrograde and anterograde motion of mitochondria [57].
Interestingly, the study by Moller and others [107] did not
detect changes to cytosolic calcium (Ca2+) levels in ALS mu-
tant SOD1-transfected cortical neurons.
Nguyen and others [69] introduced two novel mouse
models, created through neuron-specific (corticospinal tract
axons) knockout of Miro1 that demonstrated the importance
of Miro1-mediated mitochondrial motility and distribution for
maintaining neuronal functions. The study further revealed a
specific requirement for Miro1 in upper motor neuron devel-
opment and post-mitotic function, with targeted disruption of
Miro1 within the cerebral cortex that caused retrograde mito-
chondrial motility defects in cortical neurons, depletion of
mitochondria from neuronal axons within the corticospinal
tract, and progressive upper-body ALS. However, despite
the negative effects that loss of mammalian Miro1 function
exerted on mitochondrial distribution, the loss did not disrupt
calcium-regulated mitochondrial movement, mitochondrial-
mediated calcium buffering, nor mitochondrial respiratory
function. This suggests that defects in mitochondrial motility
and distribution are sufficient to cause neurological disease,
such as ALS.
Miro Proteins in Alzheimer’s Disease
Beyond PD, altered Miro function has been implicated in the
pathogenesis of other neurological disorders featuring abnor-
mal mitochondrial distribution, morphology or function.
Inhibition of dMiro has been shown to activate the PAR-1/
MARK family kinases, for example, subsequently promoting
the pathological phosphorylation of tau [31]. Abnormal phos-
phorylation and toxicity of tau, a microtubule-associated pro-
tein, has been broadly associated with neurodegenerative dis-
orders known as tauopathies [108], including AD [109, 110],
frontotemporal dementia [111, 112] and progressive
supranuclear palsy [113]. Indeed, activation of the PAR-1/
MARK-tau pathway has been demonstrated in animal models
of AD in addition to patient samples [114–117] (see Fig. 4).
Using transgenic Drosophila expressing human tau, Iijima-
Ando and colleagues demonstrated that RNAi-mediated
dMiro knockdown increased human tau phosphorylation at
the AD-related site Ser262, resulting in increased levels of
active PAR-1 and enhanced tau-induced neurodegeneration
[115]. Furthermore, knockdown of Miro produced late-onset
neurodegeneration in the fly brain, an effect that could be
suppressed by knockdown of Drosophila tau or PAR-1
[115]. Interestingly, the heterozygous Miro mutation
(miro[Sd32]) has been previously linked to mitochondrial
mislocalisation and the amyloid-β 42 (Aβ42)-induced onset
of AD symptoms in an alternate fly model [31]. Although
further investigations are required to enhance our understand-
ing of the molecular mechanism underlying the onset of am-
yloid beta plaques by Miro, these results provide initial evi-
dence for the apparent association between Miro and AD. The
essential role of Miros in ATP homeostasis has been described
above. While mitochondrial transport in both directions by
Miros is based on intracellular calcium sensing, the Miros
are also possibly involved in intracellular and intra-
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mitochondrial calcium sensing in isolation. Although a direct
connection between intra-mitochondrial calcium sensing by
Miros and neuronal function has not been established, it can-
not be completely discounted. Indeed, familial AD has been
correlated with increased Ca2+ release from ER and elevated
levels of calcium [118]. It has been proposed abnormally high
Ca2+ concentrations over time result in neurons exhibiting AD
morphology. Although calcium channel inhibitors have been
traditionally considered as therapeutic targets for AD in this
respect, it is becoming increasingly apparent that inhibitors
and modulators of Ca2+ signalling and mitochondrial function
are attractive therapeutic targets for AD treatment.
Furthermore, knockdown of dMiro has been implicated in
late-onset AD in Drosophila [115]. It therefore remains to be
seen whether Miros can also be potential targets for AD
treatment.
Concluding Remarks
It is becoming increasingly evident that the Miros function as
integrated molecular machines that regulate a wide variety of
processes, from maintaining normal mitochondrial morpholo-
gy to mitochondrial transport, in addition to participating in
quality control of mitochondria through fission and fusion
control [42, 65, 119]. We anticipate that the coming years will
see the identification of interacting partners of the Miros to
assist regulation of these processes. In such endeavours, pro-
teomic profiling promises to be an important tool for revealing
protein-protein interactions mediated through the Miros. The
molecular role of theMiros in additional cell processes such as
endoplasmic reticulum-mitochondrial complex formation,
calcium sensing and neuronal function continues to emerge,
whilst the significance of the Miros in developmental and
neuronal differentiation processes are yet to be fully
established [120–122]. It is clear that the Miros function as
unique organelle regulators in ways that have not been ob-
served in any human GTPases previously. Previously
targeting the Miros has also been shown to clearly inhibit cell
migration in oncogenic cell lines [123]. Targeting the Miros
for neurological diseases is rather an attractive option since the
structural features of theMiros varies from the traditional Ras-
like molecules and allosteric modulators developed against
the Miros may prove to be effective therapeutic agents. In
order to validate the humanMiros as a drug target to modulate
Ca2+ sensing and neuronal damage it is essential to completely
understand the molecular role of individual human Miros.
This also includes understanding the intramolecular regulation
of full-length protein and intramolecular regulation of full-
length protein and molecular conformational changes which
will provide a better understanding of mode of regulation and
intra molecular interaction capacity. Current overview ofMiro
Fig. 4 A schematic diagram showing cellular functions ofMiro GTPases.
A = PINK1 kinase phosphorylates Miro and Parkin subsequently
ubiquitinates Miro for proteosomal degradation, which interferes with
mitochondrial movement. This process is considered to be a prelude to
mitophagy, a process during which damaged mitochondrial are removed.
B = The Miros are responsible for mitochondrial transport in the
anterograde and retrograde transport in response to energy demand and
calcium concentration. C = The Miros play a significant role in
maintaining mitochondrial morphology. Mitochondrial morphology is
determined by a dynamic equilibrium between organelle fusion and
fission. The processes of mitochondrial fission and fusion are also
mediated by Miro with other GTPases like mitofusins. D = Microtubule
dynamics form ordered cytoskeletal structures that contribute to neuronal
polarity maintenance, neuronal morphology and the transportation of
cargo. Miro affects microtubule dynamics through an unknown
mechanism that may affect cell cycle and cell division in neuronal
systems [127]. Mitochondria, microtubule subunits and signalling
molecules are not drawn to scale.
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function comes from limited information available on Miro’s
structural information available for EF hands and c-terminal
GTPase domain. Biophysical studies involving Miro has been
largely focused on Miros role in mitochondrial transport
across neurons and how Miros participate as efficient compo-
nent of larger molecular assembly with Milton/Traks and
Dynein in anterograde and retrograde transports. An elegant
biophysical study that investigated the mesenchymal stem cell
(MSC) rejuvenation as a therapeutic avenue to combat human
disorders determined a compelling role of Miros in intracellu-
lar mitochondrial movement from mesenchymal stem cells to
epithelial cells [124]. Using mouse models and imaging tech-
niques using various fluorescent probes this study established
enhanced Miro1 expression increased mitochondrial donor
efficiency. This is quite significant since Miro1 overexpress-
ing MSC is seen to enhance therapeutic effects on various
models of lung inflammation and injury and therefore Miro1
overexpression is considered an effective route for various
stem cell therapies. It will therefore be useful to explore the
possibility of combining various content imaging, TIRF mi-
croscopy, and time lapse measurements in specific disease
conditions that relate to deficient mitochondrial function to
determine the wider role played by human Miros.
Computational studies involving molecular simulations
and complete structural modelling will be a valuable addition
to improve the insight into the enzymatic capabilities, regula-
tion and macromolecular interactions of Miros for work on
phosphate releasing and phosphotransfer enzyme revealed
the binding characteristics of EGFR [125]. Moreover,
analysing the unique behaviour of the individual full-length
human Miro will provide valuable clues on the enzymatic
activation and intermolecular interaction properties [126].
Therefore, future work on modelling full-length Miros and
analysing folding dynamics will be highly useful for gaining
information on dynamic rearrangement of Miros’ cytoplasmic
region interaction, EF-hand-based calcium sensing ability and
implication of mitochondrial transport in neuronal function.
This is also vital to rationalise and develop targeted therapies
in the future.
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